Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen by Andrew Whiteley, Stephen C. Ijioma, David Ray, Spencer S. Langerman, Ellen Hu, Amy Pierre, Tomer Mark, Habte Yimer

Subjects: Get full text

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial by Ya‐Lan Zhou, Jin‐Qiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Li‐Ping Su, Wen‐Ming Chen, Guang‐Zhong Yang

Subjects: Get full text

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma by Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Usmani, Mei Dong, Lin Gu, Carmen Leung, Parul Doshi, Christine Chen, Ludek Pour

Subjects: Get full text

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan by Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang

Subjects: Get full text

Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England by Sally Moore, Laura Cornic, Christina‐Jane Crossman‐Barnes, Sophie Jose, Zeyad Khalaf, Kwee Yong, Megan Soutar, Philip Woods

Subjects: Get full text

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial by Hao Yao, Shi-hui Ren, Lin-hui Wang, Ming-qiang Ren, Jiao Cai, Dan Chen, Ying He, Si-han Lai, Bai-tao Dou, Meng-jiao Li, Yan-ling Li, Ya-li Cen, Alex H. Chang, Yi Su, Ling Qiu, Fang-yi Fan

Subjects: Get full text

Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy&m... by Chen B, Guo R, Niu Y, Guo W, Wang T

Subjects: Get full text

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report by Reilly Fankhauser, Alan Lu, Adetola Kassim, Eden Biltibo

Subjects: “…relapsed refractory multiple myeloma (RRMM)…”
Get full text

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma by Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li

Subjects: “…Relapsed/Refractory multiple myeloma (R/R MM)…”
Get full text

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy by Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D

Subjects: Get full text

Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians by Rebekah Hall, Gin Nie Chua, Bonnie Macfarlane, Richard K Plante, Kun Shi, Stephanie Soltys, Arleigh McCurdy, Martine Elias, Jessy Ranger

Subjects: “…Relapsed/refractory multiple myeloma…”
Get full text

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects by Abdullah AlZahrani, Nada Alsuhebany, Imran K. Tailor, Abdullah M. Alrajhi

Subjects: “…AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; CAR T-cell, chimeric antigen receptor T-cell; CLL, chronic lymphocytic leukemia; FDA, Food and Drug Administration; IC50, half maximal inhibitory concentration; IL-6: interleukin 6; IMiD, immune-modulators; MM, multiple myeloma; ORR, overall response rate; PFS, progression-free survival; PI, proteasome inhibitor; RRMM, relapsed/refractory multiple myeloma…”
Get full text